[Skip to Navigation]
Comment & Response
May 4, 2022

Diagnosis of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors

Author Affiliations
  • 1Oncodermatology Clinic, Hospital Ruber Juan Bravo, Madrid, Spain
  • 2Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York
JAMA Dermatol. 2022;158(6):704. doi:10.1001/jamadermatol.2022.1113

To the Editor We read with great interest the analysis of a cohort of breast cancer survivors with alopecia by Bhoyrul et al.1 Determining adverse events to treatments is key in oncodermatology, such that the grading system used in oncology studies (the Common Terminology Criteria for Adverse Events)2 has 5 categories: definite, probable, possible, unlikely, or unrelated. The importance of proper causation lies in the notion that multimodal (ie, systemic therapy, radiation) and polypharmacy (multiple systemic agents) are common in cancer treatments.

Add or change institution